CNS Pharmaceuticals, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 4.75 USD (Oct 30, 2026, 2:47 PM EDT) · Market cap 6.94M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Details
| Name | CNS Pharmaceuticals, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 8 |
| Founded | 2017 |
| Ipo Date | 2019-11-08 |
| Ceo | Rami Levin |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 4.00 |
| Isin | US18978H5081 |
| Cusip | 18978H508 |
| Cik | 1729427 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Rami Levin M.B.A. | President, Chief Executive Officer and Director |
| Steve O'Loughlin M.B.A. | Chief Financial Officer |
| Eric Faulkner M.B.A., M.Sc. | Chief Technology Officer |
| Dylan Wenke M.B.A. | Chief Business Officer |
| Dr. E. Lynne Kelley F.A.C.S., M.D. | Chief Medical Officer |
Contact
| Address | 2100 West Loop South, Suite 900, Houston, Texas 77027, United States |
| Phone | 800 946 9185 |
| Website | https://cnspharma.com |